Genome-wide cell-free DNA fragmentation in patients with cancer
Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with
cancer. However, characteristics of the origins and molecular features of cell-free DNA are …
cancer. However, characteristics of the origins and molecular features of cell-free DNA are …
[HTML][HTML] Cell-free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review
SJ Schraa, KL van Rooijen, M Koopman, GR Vink… - Cancers, 2022 - mdpi.com
Simple Summary Patients with colorectal cancer without distant metastases are often cured
by surgical tumor resection. Follow-up is needed because of the risk of disease recurrence …
by surgical tumor resection. Follow-up is needed because of the risk of disease recurrence …
Impulse oscillometry: a measure for airway obstruction
GR Vink, HGM Arets, J van der Laag… - Pediatric …, 2003 - Wiley Online Library
The impulse oscillometry system (IOS) was introduced as a new technique to assess airflow
obstruction in patients who are not able to perform forced breathing maneuvers, eg, subjects …
obstruction in patients who are not able to perform forced breathing maneuvers, eg, subjects …
Two‐color multiplex ligation‐dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses
Genomic deletions and duplications play an important role in the etiology of human disease.
Versatile tests are required to detect these rearrangements, both in research and diagnostic …
Versatile tests are required to detect these rearrangements, both in research and diagnostic …
Sixty-day mortality of patients with metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection followed by systemic treatment: the …
DEW van der Kruijssen, SG Elias, GR Vink… - JAMA …, 2021 - jamanetwork.com
Importance The role of primary tumor resection (PTR) in synchronous patients with
metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent …
metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent …
Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice‐site prediction programs
MPG Vreeswijk, JN Kraan, HM van der Klift… - Human …, 2009 - Wiley Online Library
A large number of sequence variants identified in BRCA1 and BRCA2 cannot be
distinguished as either disease‐causing mutations or neutral variants. These so‐called …
distinguished as either disease‐causing mutations or neutral variants. These so‐called …
Perceived care and well-being of patients with cancer and matched norm participants in the COVID-19 crisis: results of a survey of participants in the Dutch PROFILES …
LV Van De Poll-Franse, BH De Rooij… - JAMA …, 2021 - jamanetwork.com
Importance As the resolution of the coronavirus disease 2019 (COVID-19) crisis is
unforeseeable, and/or a second wave of infections may arrive in the fall of 2020, it is …
unforeseeable, and/or a second wave of infections may arrive in the fall of 2020, it is …
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening …
ECH Breekveldt, I Lansdorp-Vogelaar… - The lancet …, 2022 - thelancet.com
Background In 2014, a population-based colorectal cancer (CRC) screening programme
was stepwise implemented in the Netherlands comprising faecal immunochemical testing …
was stepwise implemented in the Netherlands comprising faecal immunochemical testing …
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
PAH Hamers, MAG Elferink, RK Stellato… - … Journal of Cancer, 2021 - Wiley Online Library
Reported median overall survival (mOS) in metastatic colorectal cancer (mCRC) patients
participating in systemic therapy trials has increased to over 30 months. It is uncertain …
participating in systemic therapy trials has increased to over 30 months. It is uncertain …
[HTML][HTML] Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
GE Wensink, MAG Elferink, AM May, L Mol… - British journal of …, 2021 - nature.com
Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR
mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is …
mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is …